Literature DB >> 17907518

The cost of childhood asthma and its determinants in Ankara, Turkey.

N Ercüment Beyhun1, Nesrin Cilingiroğlu, Bülent E Sekerel.   

Abstract

Bronchial asthma is one of the most common chronic diseases of childhood. In recent years a consistent increase in the prevalence, and concomitantly, in the social and economic impact of the disease, has been reported. In order to provide data for the cost of pediatric asthma and its determinants in Turkish children, a study was performed in a single outpatient clinic, which encompasses a questionnaire-guided interview and retrospective evaluation of the last year files. From the 183 patients enrolled, most were males (65.6%) and atopics (63.5%), with a disease severity of mild intermittent (67.7%). Mean annual total costs per patient was US $991.7 +/- 73.2 (median = 688.8) and the largest proportion of the direct costs was due to outpatient clinic costs (48.5%). Mean cost of any hospitalization per patient was US $955.5 +/- 16.5. In multivariate analysis, the disease severity, current use of preventive drugs and current use of emergency sevice and/or current hospitalization appeared to be the main determinants of direct costs. Adequate control of the disease plays a key role in decreasing the total direct costs of pediatric asthma although it increases the medication and outpatient costs.

Entities:  

Mesh:

Year:  2007        PMID: 17907518

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  3 in total

1.  Economic Burden of Pediatric Asthma in Turkey: A Cost of Illness Study from Payer Perspective.

Authors:  Bülent Enis Şekerel; Haluk Türktaş; Sevim Bavbek; Ergün Öksüz; Simten Malhan
Journal:  Turk Thorac J       Date:  2020-07

Review 2.  Asthma costs and social impact.

Authors:  Carlos Nunes; Ana Margarida Pereira; Mário Morais-Almeida
Journal:  Asthma Res Pract       Date:  2017-01-06

Review 3.  Economic burden of asthma: a systematic review.

Authors:  Katayoun Bahadori; Mary M Doyle-Waters; Carlo Marra; Larry Lynd; Kadria Alasaly; John Swiston; J Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2009-05-19       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.